Bisphosphonates have been linked to increased risk for atypical femoral fractures (AFFs), but the usual definition of AFF excludes periprosthetic femoral fractures (PFFs) in patients with hip or knee ...

March 25, 2010 (UPDATED March 30, 2010) — Subtrochanteric and diaphyseal femur fractures are rare, even with bisphosphonate use for up to 10 years, according to the results of an analysis of 3 trials ...

Please provide your email address to receive an email when new articles are posted on . The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for ...

Atypical femoral fractures have been associated with long-term bisphosphonate treatment. 1,2 However, the underlying mechanisms remain obscure. We studied three sisters who had atypical femoral ...

Long-term bisphosphonate therapy can change bones at the microscopic level to make them more susceptible to the rare catastrophic transverse breaks known as atypical femoral fractures (AFFs), ...

Please provide your email address to receive an email when new articles are posted on . Among South-East Asian adults, bisphosphonate use in is not associated with differences in clinical outcomes or ...

The risk of atypical femur fractures increases with prolonged use of bisphosphonates, drugs commonly used to treat osteoporosis, according to a new study. The research, conducted by scientists at the ...

(HealthDay News) — Bisphosphonate use, especially over a long duration, is associated with increased risk of atypical femoral fracture, according to a study published in the September 4 issue of the ...

Labeling change adds warning about possible risks of long-term use of osteoporosis drugs The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk ...

BOSTON (Reuters) - U.S. regulators said on Wednesday they have found no link between oral bisphosphonate osteoporosis medications such as Merck & Co Inc's Fosamax and certain thigh bone fractures. The ...

Bisphosphonate use is associated with only a very low risk of atypical fractures to the subtrochanteric or diaphyseal femur, even in women who receive the drugs for up to 10 years, data from an ...